RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)- dependent ubiquitylation and proteasome-dependent degradation o...

Descripción completa

Detalles Bibliográficos
Autores: Zhou, Nan, Gutiérrez Uzquiza, Álvaro, Zheng, Xiang Yu, Chang, Renxu, Vogl, Dan T., Garfall, Alfred L., Bernabei, Luca, Saraf, Anita, Florens, Laurence, Washburn, Michael P, Illendula, Anuradha, Bushweller, John H., Busino, Luca
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/115292
Acceso en línea:https://hdl.handle.net/20.500.14352/115292
Access Level:acceso abierto
Palabra clave:577.1
577.2
Oncología
Biología molecular (Farmacia)
Bioquímica (Farmacia)
2302 Bioquímica
Descripción
Sumario:Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)- dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Using an unbiased screen based on mass spectrometry, we identified the Runt-related transcription factor 1 and 3 (RUNX1 and RUNX3) as interactors of IKZF1 and IKZF3. Interaction with RUNX1 and RUNX3 inhibits CRBN-dependent binding, ubiquitylation, and degradation of IKZF1 and IKZF3 upon lenalidomide treatment. Inhibition of RUNXs, via genetic ablation or a small molecule (AI-10-104), results in sensitization of myeloma cell lines and primary tumors to lenalidomide. Thus, RUNX inhibition represents a valuable therapeutic opportunity to potentiate IMiDs therapy for the treatment of multiple myeloma

Similares en LA Referencia